Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

1.100 -0.050 (-4.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 854,044
Open 1.170
Bid (Size) 1.100 (1,000)
Ask (Size) 1.180 (100)
Prev. Close 1.150
Today's Range 1.080 - 1.170
52wk Range 0.6434 - 2.370
Shares Outstanding 105,482,558
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
MaxCyte Q1 Earnings Call Highlights ↗
MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core... 
Via MarketBeat
Topics Earnings

Performance

YTD
-29.0%
-29.0%
1 Month
+33.8%
+33.8%
3 Month
+31.7%
+31.7%
6 Month
-31.2%
-31.2%
1 Year
-52.2%
-52.2%

More News

Read More
MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback ↗
Via Chartmill
News headline image
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Inc (NASDAQ:MXCT) Reports Q4 2025 Revenue Miss and Cautious 2026 Outlook ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Planned CFO Transition in 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
Insights into MaxCyte's Upcoming Earnings ↗
Via Benzinga
News headline image
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
From MaxCyte, Inc
Via GlobeNewswire
News headline image
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗
Via Benzinga
News headline image
Thursday's session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga

Frequently Asked Questions

Is MaxCyte, Inc. - Common Stock publicly traded?
Yes, MaxCyte, Inc. - Common Stock is publicly traded.
What exchange does MaxCyte, Inc. - Common Stock trade on?
MaxCyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MaxCyte, Inc. - Common Stock?
The ticker symbol for MaxCyte, Inc. - Common Stock is MXCT on the Nasdaq Stock Market
What is the current price of MaxCyte, Inc. - Common Stock?
The current price of MaxCyte, Inc. - Common Stock is 1.100
When was MaxCyte, Inc. - Common Stock last traded?
The last trade of MaxCyte, Inc. - Common Stock was at 06/11/26 04:00 PM ET
What is the market capitalization of MaxCyte, Inc. - Common Stock?
The market capitalization of MaxCyte, Inc. - Common Stock is 116.03M
How many shares of MaxCyte, Inc. - Common Stock are outstanding?
MaxCyte, Inc. - Common Stock has 116M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.